Cervical dysplasia (cervical intraepithelial neoplasia or CIN) caused by HPV

Phase II

This study is ongoing, but not recruiting participants

This research study of an investigational synthetic DNA vaccine is enrolling women with CIN 2/3 or CIN 3 associated with HPV type 16 or HPV type 18. The goal is to evaluate whether the cervical lesions will regress to CIN 1 or less within nine months after the first treatment in this study. A secondary goal will be to assess the clearance of HPV 16 and HPV 18.

Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) Delivered IM Followed by Electroporation with CELLECTRA®-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 with Documented HPV 16 or 18

HPV-003 Clinical Research Study

VGX-3100

For more information please go to the study protocol.



Head and neck cancer caused by HPV

Phase I/IIa

This study is currently recruiting participants

This is a Phase I/IIa, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccine (VGX-3100 and INO-9012) delivered by electroporation to subjects with HPV 16 and HPV 18 associated head and neck squamous cell cancer.

Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma

HPV-005 Clinical Research Study

INO-3112 (VGX-3100 and INO-9012)

For more information please go to the study protocol.




Cervical cancer caused by HPV

Phase I/IIa

This study is currently recruiting participants

This is an open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccine (VGX-3100 and INO-9012) delivered by electroporation to female subjects with HPV 16 or 18 positive cervical carcinoma.

A Study of VGX-3100 and INO-9012 DNA Vaccine With Electroporation in Patients With Cervical Cancer

HPV-004 Clinical Research Study

INO-3112 (VGX-3100 and INO-9012)

For more information please go to the study protocol.




Aerodigestive cancer caused by HPV

Phase I

This study is currently recruiting participants

This is a phase I, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3106 alone or in combination with INO-9012 delivered by electroporation to subjects with HPV-6 associated aerodigestive malignancies.

Pilot Study of HPV Specific Immunotherapy in Subjects with HPV-6 Associated Aerodigestive Malignancies

HPV-006 Clinical Research Study

INO-3106 + INO-9012

For more information please go to the study protocol.